𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B

✍ Scribed by MinDe Zeng; YiMin Mao; GuangBi Yao; Hao Wang; JinLin Hou; YaoZong Wang; Beulah N. Ji; Chai-Ni P. Chang; Keith F. Barker

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
279 KB
Volume
44
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily. There was a significant difference in reduction of serum hepatitis B virus (HBV) DNA after 12 weeks between subjects who received ADV and those who received the placebo (3.4 and 0.1 log10 copies/mL, respectively, P < .001). Further reductions in serum HBV DNA and increases in the proportion of subjects with an HBV DNA level of at most 10(5) copies/mL, with HBV DNA undetectable, and with ALT normalization were observed in ADV-treated subjects at week 52 (median HBV DNA reduction of 4.5 log(10) copies/mL, 67% with HBV DNA

📜 SIMILAR VOLUMES

Telbivudine versus lamivudine in Chinese
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial
✍ Jinlin Hou; You-Kuan Yin; Daozhen Xu; Deming Tan; Junqi Niu; Xiaqiu Zhou; Yuming 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue, with lamivudin

Early hepatitis B virus DNA reduction in
Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
✍ Nancy Leung; Cheng-Yuan Peng; Hie-Won Hann; Jose Sollano; Judy Lao-Tan; Chao-Wei 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB 👁 2 views

This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB). Sixty-nine nucleoside-naïve CHB patients with baseline HBV DNA of 10(8) copi

Phase 1B, randomized, double-blind, dose
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
✍ John G. McHutchison; Bruce R. Bacon; Stuart C. Gordon; Eric Lawitz; Mitchell Shi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB 👁 1 views

CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter Phase 1b trial, 60 HCV-positive patients (50 genotype 1 HCV) were randomized and

A randomized controlled trial of thymosi
A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B
✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission

A randomized double-blind controlled tri
A randomized double-blind controlled trial of phosphorylcholine-coated tympanostomy tube versus standard tympanostomy tube in children with recurrent acute and chronic otitis media
✍ Paul Hong; Neil Smith; Liane B. Johnson; Gerard Corsten 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract ## Objective: To compare the postoperative complication rates of phosphorylcholine‐coated fluoroplastic tympanostomy tubes versus uncoated fluoroplastic tympanostomy tubes. ## Methods: A prospective randomized double‐blind controlled trial in children with recurrent acute otitis medi

Final results of a double-blind, placebo
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
✍ Paul J. Pockros; Lennox Jeffers; Nezam Afdhal; Zachary D. Goodman; David Nelson; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB 👁 2 views

## Interferon-␥1b (IFN-␥1b ) is a pleiotropic cytokine that displays antifibrotic, antiviral, and antiproliferative activity. A total of 502 patients with compensated liver disease and an Ishak fibrosis score of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these pati